Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis Complicated by a Parasternal Granulocytic Sarcoma
نویسندگان
چکیده
Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and granulocytic sarcoma are two rare myeloid neoplasms. RARS-T is a Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) characterized by overlapping myeloproliferative (platelets count higher than 450x109/L associated with proliferation of large atypical megakaryocytes similar than those observed in essential thrombocythemia) and myelodysplastic features (dysplastic erythroid proliferation with ring sideroblasts >15%). RARS-T molecular pattern also exhibited myelodysplastic and myeloproliferative overlap with frequent SF3B1 and JAK2 mutations, justifying its classification in MDS/MPN disorders. Granulocytic Sarcoma also referred as myeloid sarcoma or chloroma are rare extramedullary tumors of immature myeloid cells that partially or totally efface the tissue architecture. Extramedullary involvements include a large variety of clinical significant phenomena that often pose diagnosis problems. Granulocytic sarcoma may develop de novo or concurrently with acute myeloid leukemia or myeloproliferative neoplasms. However, no previous case of granulocytic sarcoma associated to myelodysplastic/myeloproliferative neoplasms has been reported. Herein, we report a case of RARS-T revealed by an asymptomatic thrombocytosis complicated by a granulocytic sarcoma ten months after initial diagnosis. This extramedullary megakaryoblastic mass invaded the sternum and the parietal soft tissues without associated myeloid leukemia.
منابع مشابه
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
BACKGROUND Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its...
متن کاملRefractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis Complicated by Massive Splenomegaly Treated with Lenalidomide Resulting in Resolution of Splenomegaly but Severe and Prolonged Pancytopenia
Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematological malignancy that combines features of both a myeloproliferative and myelodysplastic disorder. There have been recent reports of the successful treatment of anemia in 2 patients with RARS-T with lenalidomide. Here we report the successful treatment of massive splenomegaly in a patient with a...
متن کاملRefractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).
A 75-year-old woman who was previously healthy was investigated for chronic anemia. Her hemoglobin was 94 g/L with a mean corpuscular volume of 108 fL, white cell counts were normal, and platelet count was high (480 3 10/L). Blood film showed marked red cell anisocytosis with dimorphic pattern, stomatocytes, no neutrophil dysplasia, and no blasts (panel A-B). Bone marrow aspirate smear demonstr...
متن کاملAn Active Isodicentric X Chromosome in a Case of Refractory Anaemia with Ring Sideroblasts Associated with Marked Thrombocytosis
Refractory anaemia with ring sideroblasts and marked thrombocytosis (RARS-T) is a provisional entity in the World Health Organization (WHO) classification. It displays features characteristic of both myelodysplastic syndrome and myeloproliferative neoplasia plus ring sideroblasts ≥15% and marked thrombocytosis. Most patients with RARS-T show a normal karyotype. We report a 76-year-old woman dia...
متن کاملTreatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations
Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematologic malignancy that often results in transfusion dependency and a hypercoagulable state. This rare disease currently lacks formal guidelines for treatment; however, various case reports have demonstrated efficacy in the use of lenalidomide. This immunomodulatory drug has shown promise in patient...
متن کامل